Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renervix
- Development stage
- Unknown
- Lead developer
- Alfa Intes
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Renervix is an ophthalmic gel medical device developed by Alfa Intes for corneal neuroprotection and nerve regeneration. The formulation contains 0.3% cross-linked hyaluronic acid, which provides prolonged lubrication and viscoelastic support by adhering to the corneal surface for an extended period. It is enriched with a nutrient complex including vitamin B12 (cyanocobalamin) to accelerate corneal re-epithelialization, vitamin B6 (pyridoxamine) to stimulate the regrowth of corneal nerve endings, and taurine to support nerve health and neutralize oxidative stress in epithelial cells. Renervix is primarily indicated to support the physiological repair of the cornea and promote reinnervation following anterior segment surgery or corneal abrasions.
- Brand names
- Renervix
Beyond the preview
Go deeper on Renervix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Renervix.